JMHLY 0HLMA.L 0FNV.TO -0.02DFY.TO 1.12AGF.B.TO -0.18CDR.TO -0.07BLX -0.36KINS 0.09
Bristol Myers Squibb (BMY)

NYSE:BMY

Bristol Myers Squibb (BMY)

60.16
-0.58 (0.95%)
as of Jul 20, 2026, 8:00:00 pm Market Open.
160 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 20, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Bristol Myers Squibb (BMY-N) has garnered mixed reviews from experts, highlighting both its potential and setbacks. While some analysts praise its solid dividend yield, promising drug pipeline, and recent earnings performance that exceeded expectations, others express concerns regarding the disappointing sales of its Cobenfy drug. Recent financial results indicate a modest sales growth of 3% and a significant 18% increase in its growth portfolio, albeit with a downturn in legacy drugs. Additionally, the company's management has raised its revenue guidance for 2025, which provides a glimmer of optimism for future performance. Overall, there is cautious optimism about a possible rebound if the growth portfolio continues to outperform older products.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Undervalued
review icon
Similar
EliLilly, LLY
DON'T BUY

Bristol Myers Squibb(BMY)

Jan 02, 2003
Has had a lot of problems. Starting to clear up, but will take awhile.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$24.03

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Bristol Myers Squibb(BMY)

Dec 27, 2002
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$23.35

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Bristol Myers Squibb(BMY)

Oct 07, 2002
Has had problems in manufacturing, shipping and FDA approvals. Exoects slow earnings growth.
Photo of Brad WillockBrad WillockUnlock Rating
$21.90

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Sep 04, 2002
Likes the valuations. Good balance sheet and good earnings.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$24.89

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Aug 30, 2002
Looks cheap. There is an SEC investigation going on.
Photo of Ross HealyRoss HealyUnlock Rating
$24.95

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Bristol Myers Squibb(BMY)

Aug 30, 2002
Now is a good time for drug stocks, but this company has corporate problems.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$24.95

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Aug 29, 2002
9.25% dividend. Has been hit hard. Stable cash flow.
Photo of Arthur HeinmaaArthur HeinmaaUnlock Rating
$24.29

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Bristol Myers Squibb(BMY)

Aug 28, 2002
Has been oversold. Very cheap. Could be a takeover.
Photo of Jim DoakJim DoakUnlock Rating
$25.06

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Bristol Myers Squibb(BMY)

Aug 23, 2002
Could drop. Prefers generic drugs.
Photo of David BurrowsDavid BurrowsUnlock Rating
$25.43

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Aug 20, 2002
Good drug company, but had difficulties getting FDA approvals. Good dividend. Cheap.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$23.78

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Aug 06, 2002
Made some poor moves. Still a triple A company.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$22.43

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Bristol Myers Squibb(BMY)

Jul 24, 2002
(Was a top pick on May 23. Down 31%). Fell with health care. Price looks very good.
Photo of Ross HealyRoss HealyUnlock Rating
$20.55

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Jul 03, 2002
Trading at 5 X Book. Good dividends. New drug has approval.
Photo of David BaskinDavid BaskinUnlock Rating
$24.67

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
BUY

Bristol Myers Squibb(BMY)

Jul 02, 2002
Likes the drug sector. Prefers Pfizer.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$24.40

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Bristol Myers Squibb(BMY)

Jun 27, 2002
Doesn't expect much growth, plus there are some issues.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$26.21

Stock price when the opinion was issued

$60.16

As of Jul 20, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 210 of 221 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

WSP.TO -3.18$178.17
MURGF 0$592.945
MSFT 8.47$402.29
UN -0.951$25.2741
TIH.TO -7.66$228.1

Today's Top Picks

JMHLY 0$63.05
HLMA.L 0$2527
FNV.TO -0.02$281.28
DFY.TO 1.12$79.4
AGF.B.TO -0.18$22.71

Popular Articles

Latest Sell Signals

CNQ.TO 0.46$61.88
SNDK 36.13$1390.95
CLF -0.3$8.98
BNS.TO -2.87$122.41
LOGI -1.05$101.78

Most Recent Experts

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like